Almirall stock
ALM.MCBMEAlmirall, S.A., HealthcareISIN ES0157097017
45Score 45 out of 100, Weak
Price and trend
61 / 100
Price history
−13% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 5.2% below it.
Since May 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is 22% below its 52-week high. Largest decline in 19 years: 72% (October 2007 to October 2008).
Chart figures for advanced users
- SMA 50$11.59
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$12.66
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$10.94
- The lowest closing price of the last twelve months.
- Resistance$15.38
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Almirall, S.A. belongs to the Drug Manufacturers (Specialty & Generic) industry (Spain) and, with a market value of $2.61B, is number 49 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.23B (up 12.4% year on year) and earnings of $51.41M (up 355.3%).
- For fiscal 2026, analysts expect on average revenue of $1.36B (up 10.4%) and adjusted earnings per share of $0.44 (up 43.6%).
Show more
- MEQIRI Score 45 out of 100 (Weak): rank 458 of 714 in Healthcare, median 53.
- The P/E is 49 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 33.1).
- Our model puts fair value at $12.68, with the price 5% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 291% of earnings over the last 12 months.Fundamentals 56
- Analysts expect strong earnings growthUp 27.2% a year through 2028 (estimates from 9 analysts).
Weaknesses
- Richly valuedP/E 49, Drug Manufacturers (Specialty & Generic) median 19.3, own median 33.1.Valuation 47
- DilutionShare count up 23% since 2020.Capital allocation 24
- Revenue shrinkingRevenue down 7.3% a year since 2020.Growth 19
Its standout strength is stability, while capital allocation and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 44 to 45.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- calm price action
- low growth grade (crashed less often in the backtest)
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $9.06 and expensive above $21.14 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $20.63 (cash-flow model) and $4.73 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8%. At 9% the fair value would be $10.89, at 7% it would be $15.38.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 34.3% on the twelve months before. Revenue has stayed largely stable since 2006.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 41%, operating 6%, net 4%.
Debt & balance sheet
latest quarterLow debt, and interest is adequately covered.
Earnings
- Next earnings
- 22 Feb 2027in 102 days
- Last reported
- 9 Nov 2026EPS reported $0.09 (expected $0.09)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.44+0.8%
- Revenue
- $1.36B−0.2%
- Earnings per share
- $0.59+1.6%
- Revenue
- $1.49B−0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +1.8%2026 guidance reiterated, with growth expected to pick up towards the second half of the year.
“This is why we are reiterating our full year 2026 guidance with growth expected to pick up towards the second half of the year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 24 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Almirall
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 45
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Siegfried HoldingSFZN.SW $3.77B55
- Bausch Health CompaniesBHC $3.13B61
- Regencell Bioscience HoldingsRGC $2.68B31
- HUTCHMED (China)HCM $2.63B45
- PerrigoPRGO $2.3B48
- Trulieve CannabisTRLV $2.17B48
- Dermapharm HoldingDMP.DE $2.13B68
- FagronFAGR.BR $1.99B70
ETFs that hold Almirall
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.29% | 0.40% | €575.19M |
| WisdomTree Europe SmallCap Dividend UCITS ETFWTES | 0.22% | 0.38% | €86.74M |
| iShares MSCI EMU Small Cap UCITS ETFSXRJ | 0.16% | 0.58% | €834.67M |
Show 5 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.10% | 0.23% | €319.31M |
| Xtrackers Spain UCITS ETF 1DXESD | 0.10% | 0.30% | €509.27M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.06% | 0.30% | €3.43B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.35% | €434.1M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.03% | 0.30% | €810.11M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 4 Apr 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.